What is the share price of Divi's Laboratories Ltd (DIVISLAB) today?
The share price of DIVISLAB as on 12th June 2026 is ₹6719.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Divi's Laboratories Ltd (DIVISLAB) share?
The past returns of Divi's Laboratories Ltd (DIVISLAB) share are- Past 1 week: 1.44%
- Past 1 month: -0.66%
- Past 3 months: 4.77%
- Past 6 months: 3.51%
- Past 1 year: -0.95%
- Past 3 years: 94.11%
- Past 5 years: 53.55%
What are the peers or stocks similar to Divi's Laboratories Ltd (DIVISLAB)?
The peers or stocks similar to Divi's Laboratories Ltd (DIVISLAB) include:What is the dividend yield % of Divi's Laboratories Ltd (DIVISLAB) share?
The current dividend yield of Divi's Laboratories Ltd (DIVISLAB) is 0.45.What is the market cap of Divi's Laboratories Ltd (DIVISLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Divi's Laboratories Ltd (DIVISLAB) is ₹176682.61 Cr as of 12th June 2026.What is the 52 week high and low of Divi's Laboratories Ltd (DIVISLAB) share?
The 52-week high of Divi's Laboratories Ltd (DIVISLAB) is ₹7071.50 and the 52-week low is ₹5636.50.What is the PE and PB ratio of Divi's Laboratories Ltd (DIVISLAB) stock?
The P/E (price-to-earnings) ratio of Divi's Laboratories Ltd (DIVISLAB) is 68.80. The P/B (price-to-book) ratio is 11.80.Which sector does Divi's Laboratories Ltd (DIVISLAB) belong to?
Divi's Laboratories Ltd (DIVISLAB) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Divi's Laboratories Ltd (DIVISLAB) shares?
You can directly buy Divi's Laboratories Ltd (DIVISLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Divi's Laboratories Ltd
DIVISLAB Share Price
NSE₹6,719.500.96% (+64.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
DIVISLAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
DIVISLAB Performance & Key Metrics
DIVISLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 68.80 | 11.80 | 0.45% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 41.70 | 6.09 | 0.56% |
63%
Analysts have suggested that investors can buy this stock
from 24 analysts
Price Upside
Earnings Growth
Rev. Growth
DIVISLAB Company Profile
Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. Its products include Generic APIs, Intermediates, Peptide Building Blocks and Carotenoids.
SYNGENE
PE Ratio
56.93
56.93
1Y Return
32.39%
32.39%
Buy Reco %
62.50
62.50
AARTIPHARM
PE Ratio
32.30
32.30
1Y Return
32.12%
32.12%
Buy Reco %
0.00
0.00
PE Ratio
28.39
28.39
1Y Return
38.86%
38.86%
Buy Reco %
0.00
0.00
VIMTALABS
PE Ratio
30.04
30.04
1Y Return
6.96%
6.96%
Buy Reco %
0.00
0.00
PE Ratio
31.68
31.68
1Y Return
35.13%
35.13%
Buy Reco %
0.00
0.00
DIVISLAB Sentiment Analysis
DIVISLAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
DIVISLAB Stock Summary · May 2026
Management framed the quarter as one of strong revenue growth and heavy investment, with full‑year consolidated total income at ₹11,067 crore and FY26 profit before tax of ₹3,388 crore. They struck a pragmatic tone, emphasizing execution of an elevated capex program (FY26 capex ~₹2,500 crore with Kakinada reconfirmed at ~₹1,500 crore and ~₹600 crore already capitalized), continued customer engagement across custom synthesis and peptides, and proactive supply‑chain measures that avoided production stoppages despite geopolitical disruptions. Management acknowledged clear tension between rising sales and margin compression — operating margins settled near ~32% versus historical ~37–38% — driven by generic pricing pressure and elevated raw‑material and freight costs, even as contractual pass‑throughs and long‑term agreements have mitigated some impact. They reiterated that converting new capacity to revenue is timing‑variable (historically ~6 months–3 years; management views ~2 years as an optimistic benchmark), that gadolinium commercialization awaits customer regulatory approvals, that next‑fiscal capex should remain broadly constant absent a major new project, and that freight and inventory dynamics will influence near‑term performance.
DIVISLAB Stock Growth Drivers
DIVISLAB Stock Growth Drivers
6Disciplined operational and supply‑chain resilience
The company demonstrated disciplined execution that preserved operational stability through external disruption, maintaining supply continuity
Custom synthesis and peptide capabilities nearing commercialization with expanded capacity
A deep, diversified custom‑synthesis pipeline with multiple molecules advancing toward near‑commercialization positions the company to
DIVISLAB Stock Challenges
DIVISLAB Stock Challenges
6Geopolitical-driven supply-chain disruption and persistent freight cost pressure
Escalating geopolitical tensions in West Asia materially disrupted trade routes and logistics, producing port congestion,
Concentrated import dependence and ongoing raw-material sourcing shortages
The company faces concentrated sourcing risk for key inputs—most notably methanol, imported solvents and Middle‑East‑sourced
DIVISLAB Forecast
DIVISLAB Forecasts
Price
Revenue
Earnings
DIVISLAB Share Price Forecast
DIVISLAB Share Price Forecast
2026
Current
₹6,655.50
Baseline
Forecast for Jun 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹6,655.50
Baseline
Forecast for Jun 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
DIVISLAB Company Revenue Forecast
DIVISLAB Company Revenue Forecast
2026
Current
₹11.07
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹11.07
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
DIVISLAB Stock EPS (Earnings Per Share) Forecast
DIVISLAB Stock EPS (Earnings Per Share) Forecast
2026
Current
₹96.75
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹96.75
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
DIVISLAB
DIVISLAB
Income
Balance Sheet
Cash Flow
Quarterly Normal View
DIVISLAB Income Statement
DIVISLAB Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,950.00 | 2,382.00 | 2,197.00 | 2,444.00 | 2,401.00 | 2,671.00 | 2,529.00 | 2,860.00 | 2,692.00 | 2,986.00 | ||||||||||
Operating & Other expenses | 1,366.00 | 1,572.00 | 1,496.00 | 1,622.00 | 1,576.00 | 1,699.00 | 1,681.00 | 1,827.00 | 1,788.00 | 1,897.00 | ||||||||||
EBITDA | 584.00 | 810.00 | 701.00 | 822.00 | 825.00 | 972.00 | 848.00 | 1,033.00 | 904.00 | 1,089.00 | ||||||||||
| Depreciation/Amortization | 95.00 | 95.00 | 97.00 | 99.00 | 99.00 | 107.00 | 112.00 | 113.00 | 118.00 | 120.00 | ||||||||||
| PBIT | 489.00 | 715.00 | 604.00 | 723.00 | 726.00 | 865.00 | 736.00 | 920.00 | 786.00 | 969.00 | ||||||||||
| Interest & Other Items | 0.00 | 2.00 | 0.00 | 1.00 | 0.00 | 1.00 | 3.00 | 8.00 | 6.00 | 6.00 | ||||||||||
| PBT | 489.00 | 713.00 | 604.00 | 722.00 | 726.00 | 864.00 | 733.00 | 912.00 | 780.00 | 963.00 | ||||||||||
| Taxes & Other Items | 131.00 | 175.00 | 174.00 | 212.00 | 137.00 | 202.00 | 188.00 | 223.00 | 197.00 | 212.00 | ||||||||||
| Net Income | 358.00 | 538.00 | 430.00 | 510.00 | 589.00 | 662.00 | 545.00 | 689.00 | 583.00 | 751.00 | ||||||||||
| EPS | 13.50 | 20.25 | 16.20 | 19.20 | 22.20 | 24.93 | 20.49 | 25.97 | 21.98 | 28.31 |
DIVISLAB Company Updates
DIVISLAB Stock Peers
DIVISLAB Past Performance & Peer Comparison
DIVISLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Divi's Laboratories Ltd | 68.80 | 11.80 | 0.45% |
| Syngene International Ltd | 56.93 | 3.81 | 0.28% |
| Aarti Pharmalabs Ltd | 32.30 | 2.84 | 0.56% |
| Dishman Carbogen Amcis Ltd | 28.39 | 0.47 | — |
DIVISLAB Stock Price Comparison
Compare DIVISLAB with any stock or ETFCompare DIVISLAB with any stock or ETF
DIVISLAB
DIVISLAB Holdings
DIVISLAB Shareholdings
DIVISLAB Promoter Holdings Trend
DIVISLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
DIVISLAB Institutional Holdings Trend
DIVISLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
DIVISLAB Shareholding Pattern
DIVISLAB Shareholding Pattern
DIVISLAB Shareholding History
DIVISLAB Shareholding History
Foreign Institutions
Mutual Funds Invested in DIVISLAB
Mutual Funds Invested in DIVISLAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding Divi's Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2452% | Percentage of the fund’s portfolio invested in the stock 2.62% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 8/138 (+4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7668% | Percentage of the fund’s portfolio invested in the stock 2.53% | Change in the portfolio weight of the stock over the last 3 months 0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/62 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6707% | Percentage of the fund’s portfolio invested in the stock 1.18% | Change in the portfolio weight of the stock over the last 3 months 0.35% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/78 (+2) |
Compare 3-month MF holding change on Screener
smallcases containing DIVISLAB stock
smallcases containing DIVISLAB stock
Looks like this stock is not in any smallcase yet.
DIVISLAB Events
DIVISLAB Events
DIVISLAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DIVISLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.45%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.51 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
DIVISLAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DIVISLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.45%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.51 every year
DIVISLAB Upcoming Dividends
DIVISLAB Upcoming Dividends
Cash Dividend
Ex DateEx DateJul 24, 2026
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Jul 24, 2026
DIVISLAB Past Dividends
DIVISLAB Past Dividends
Cash Dividend
Ex DateEx DateJul 25, 2025
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Jul 25, 2025
Cash Dividend
Ex DateEx DateAug 2, 2024
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Aug 2, 2024
Cash Dividend
Ex DateEx DateAug 11, 2023
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Aug 11, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 17, 2021
Final
Final | Div/Share: ₹20.00
Dividend/Share
₹20.00
Ex DateEx Date
Aug 17, 2021
DIVISLAB Stock News & Opinions
DIVISLAB Stock News & Opinions
Articles & Videos
Corporate
Corporate
Divis Laboratories schedules AGMDivis Laboratories announced that the 36th Annual General Meeting(AGM) of the company will be held on 10 August 2026.
2 weeks agoCapital Market - Live
Corporate
Corporate
Board of Divis Laboratories recommends final dividendDivis Laboratories announced that the Board of Directors of the Company at its meeting held on 23 May 2026, inter alia, have recommended the final dividend of Rs 30 per equity Share (i.e. 1500%) , subject to the approval of the shareholders.
2 weeks agoCapital Market - Live
Spotlight
Spotlight
Divis Lab Q4 PAT climbs 13% YoY; recommends final dividend of Rs 30/shareRevenue from operations grew 9.52% YoY to Rs 2,831 crore in Q4 FY26 versus Rs 2,585 crore in Q4 FY25. Profit before tax (PBT) stood at Rs 963 crore, up 11.46% YoY from Rs 864 crore in the corresponding period last year. Total expenses rose 11.95% YoY to Rs 2,023 crore in Q4 FY26, with the cost of materials at Rs 1,214 crore (up 30.4% YoY) and employee benefit expenses at Rs 381 crore (up 8.86% YoY) during the period under review. The company reported a forex gain of Rs 90 crore in Q4 FY26 as against a forex gains of Rs 10 crore for the corresponding quarter of the previous year. On a full-year basis, the company's consolidated net profit rose 17.21% to Rs 2,568 crore on a 12.82% rise in revenue to Rs 10,560 crore in FY26 over FY25. The company's board has recommended a final dividend of Rs 30 per equity share of face value Rs 2 (1,500%) for FY26, subject to shareholder approval at the 36th AGM. The AGM will be held on 10 August 2026, with 24 July 2026 as the record date for dividend eligibility. Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients. Shares of Divis Laboratories rose 0.36% to settle at Rs 6,885 on 22 May 2026.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Earnings
Divi's Laboratories consolidated net profit rises 13.44% in the March 2026 quarterNet profit of Divi's Laboratories rose 13.44% to Rs 751.00 crore in the quarter ended March 2026 as against Rs 662.00 crore during the previous quarter ended March 2025. Sales rose 9.52% to Rs 2831.00 crore in the quarter ended March 2026 as against Rs 2585.00 crore during the previous quarter ended March 2025. For the full year,net profit rose 17.21% to Rs 2568.00 crore in the year ended March 2026 as against Rs 2191.00 crore during the previous year ended March 2025. Sales rose 12.82% to Rs 10560.00 crore in the year ended March 2026 as against Rs 9360.00 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2831.002585.00 10 10560.009360.00 13 OPM %32.9934.27 -32.5931.71 - PBDT1083.00971.00 12 3925.003318.00 18 PBT963.00864.00 11 3462.002916.00 19 NP751.00662.00 13 2568.002191.00 17 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Corporate
Divis Laboratories to table resultsDivis Laboratories will hold a meeting of the Board of Directors of the Company on 23 May 2026.
4 weeks agoCapital Market - Live
Spotlight
Spotlight
Divis Laboratories Ltd gains for third straight sessionDivis Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 6722, up 1.07% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 24018.3. The Sensex is at 76839.15, down 0.23%. Divis Laboratories Ltd has gained around 14.91% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 10.1% in last one month and is currently quoting at 23568.95, up 2.16% on the day. The volume in the stock stood at 1.33 lakh shares today, compared to the daily average of 2.86 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 6779, up 1.68% on the day. Divis Laboratories Ltd is up 9.34% in last one year as compared to a 1.62% slide in NIFTY and a 12.19% slide in the Nifty Pharma index.The PE of the stock is 68.65 based on TTM earnings ending December 25.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Spotlight
Divis Laboratories Ltd eases for fifth straight sessionDivis Laboratories Ltd dropped for a fifth straight session today. The stock is quoting at Rs 5824.5, down 1.39% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 1.28% on the day, quoting at 22388.45. The Sensex is at 72170.86, down 1.32%.Divis Laboratories Ltd has eased around 7.78% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 4.37% in last one month and is currently quoting at 22011.6, down 1.5% on the day. The volume in the stock stood at 3.7 lakh shares today, compared to the daily average of 2.86 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 5847.5, down 1.5% on the day. Divis Laboratories Ltd jumped 1.07% in last one year as compared to a 3.71% slide in NIFTY and a 1.21% spurt in the Nifty Pharma index.The PE of the stock is 60.95 based on TTM earnings ending December 25.
2 months agoCapital Market - Live
Earnings
Earnings
Divi's Laboratories consolidated net profit declines 1.02% in the December 2025 quarterNet profit of Divi's Laboratories declined 1.02% to Rs 583.00 crore in the quarter ended December 2025 as against Rs 589.00 crore during the previous quarter ended December 2024. Sales rose 12.29% to Rs 2604.00 crore in the quarter ended December 2025 as against Rs 2319.00 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales2604.002319.00 12 OPM %34.1832.04 - PBDT972.00825.00 18 PBT854.00726.00 18 NP583.00589.00 -1 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Divis Laboratories schedules board meetingDivis Laboratories will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Spotlight
Divis Laboratories Ltd drops for fifth straight sessionDivis Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 6125.5, down 1.77% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.61% on the day, quoting at 25538.45. The Sensex is at 83093.05, down 0.57%.Divis Laboratories Ltd has eased around 5.93% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 3.39% in last one month and is currently quoting at 22217.05, down 0.3% on the day. The volume in the stock stood at 2.19 lakh shares today, compared to the daily average of 4.16 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 6138, down 1.86% on the day. Divis Laboratories Ltd jumped 2.08% in last one year as compared to a 9.4% rally in NIFTY and a 0.15% fall in the Nifty Pharma index.The PE of the stock is 65.83 based on TTM earnings ending September 25.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 11.7%, vs industry avg of 10.53%
Over the last 5 years, market share decreased from 55.28% to 51.02%
Over the last 5 years, net income has grown at a yearly rate of 9.74%, vs industry avg of 7.25%